
As the future chairman of Ferring Pharmaceuticals, Lars Rebien Sørensen will soon be taking on his first board role within the pharmaceutical industry.
Although he is a high profile figure in the Danish pharmaceutical industry, and in spite of his many years as the top executive at Novo Nordisk and his current role as the chairman of the Novo Nordisk Foundation, he has never before sat on the board of a pharmaceutical company.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app